Kim Keck

Board Director

Director

Oak Street Health, Inc.Evolent Health, Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 1 buy · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€182k

▼ Sales (0 ops.)

—

Latest filing published 08 Jun 2026 for Evolent Health, Inc..

Filing timeline

BuySale

Kim Keck

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

100%

T+90 mean return

+18.9%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Kim Keck: trading record in brief

Kim Keck is a declared insider at 2 companies (board member); the most frequent names are Evolent Health, Inc. and Oak Street Health, Inc. In total, 14 filings cover trades dated from 10 August 2020 to 4 June 2026.

No open-market sale appears; the market trades are 2 purchases worth €182k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 11 share grants.

Most recently, on 8 June 2026, the filings show a share grant in Evolent Health, Inc. The last purchase on record was published on 10 March 2025, which is 594 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.